Nebol (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebol, is a beta‑1 selective adrenergic receptor blocker presented as an oral tablet for oral use. It reduces systemic vascular resistance and lowers elevated blood pressure in adult patients with hypertension, offering a vasodilatory effect through nitric oxide enhancement while maintaining cardiac output.

GNH USA supplies Nebol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing quality‑assured products that meet European Union standards. The company ensures consistent batch release testing and regulatory compliance for global distribution.

Nebivolol is indicated for conditions related to elevated arterial pressure and cardiovascular regulation.

Hypertension: reduces systolic and diastolic blood pressure, improving overall cardiovascular risk profile. Essential hypertension: provides long‑term blood pressure control with a favorable effect on heart rate. High blood pressure: assists in maintaining target blood pressure levels as part of antihypertensive therapy.

Nebivolol may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache - Dizziness - Fatigue - Bradycardia - Nausea

Serious or Rare Side Effects: - Severe bradycardia or heart block - Acute hypotension - Bronchospasm in susceptible individuals - Allergic reactions such as rash or angioedema

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure patient safety.

Blood pressure monitoring: regularly assess blood pressure and heart rate after initiation. Cardiac function assessment: evaluate for existing heart failure or conduction disorders before use. Respiratory caution: use with care in patients with asthma or chronic obstructive pulmonary disease. Discontinuation: avoid abrupt cessation; taper dose to prevent rebound hypertension. Renal/hepatic impairment: adjust dosing in moderate to severe renal or hepatic dysfunction. Store at below 25°C: keep in the original packaging, protect from moisture and light.

Nebivolol can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Combined use with other β‑blockers: may cause excessive bradycardia or AV block. - Calcium channel blockers verapamil or diltiazem: increase plasma levels and risk of cardiac conduction disturbances. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): raise nebivolol concentrations, enhancing adverse effects.

Moderate Interactions (Monitor Closely): - Diuretics: additive blood pressure lowering may lead to hypotension. - ACE inhibitors or ARBs: monitor for excessive hypotensive response. - NSAIDs: may reduce antihypertensive effect of nebivolol.